Run by a veteran of drug R&D for Alzheimer’s disease, Alzheon is betting that a smart trial design and a little chemistry work could turn a failed drug for the memory-robbing disorder into a success. Alzheon president and CEO Martin Tolar says the company will spend the next six months “fine tun[ing]” things, like developing a once-a-day pill of its drug, now called ALZ-801. Then it’s on to a Phase 2/3 trial, which Alzheon aims to start by the end of the year. The $10 million will get Alzheon to that point—Tolar says Alzheon plans to raise more cash later this year to push through the coming trial.
As quoted from xconomy.com. Read the full article here
Photo “My Mother’s Hands” courtesy of Ann Gordon via a Creative Commons license.